Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 19595305)

1.

Ras signaling and therapies.

Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F.

Adv Cancer Res. 2009;102:1-17. doi: 10.1016/S0065-230X(09)02001-6. Review.

PMID:
19595305
2.

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway.

Sebolt-Leopold JS.

Clin Cancer Res. 2008 Jun 15;14(12):3651-6. doi: 10.1158/1078-0432.CCR-08-0333.

3.

Ras family signaling: therapeutic targeting.

Cox AD, Der CJ.

Cancer Biol Ther. 2002 Nov-Dec;1(6):599-606. Review.

4.

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

Friday BB, Adjei AA.

Clin Cancer Res. 2008 Jan 15;14(2):342-6. doi: 10.1158/1078-0432.CCR-07-4790.

5.

Cancer targets in the Ras pathway.

Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F.

Cold Spring Harb Symp Quant Biol. 2005;70:461-7. Review.

PMID:
16869784
6.

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F.

Cancer Res. 2009 May 15;69(10):4286-93. doi: 10.1158/0008-5472.CAN-08-4765. Epub 2009 Apr 28.

7.

Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?

Shinohara N, Koyanagi T.

Urol Res. 2002 Oct;30(5):273-81. Epub 2002 Sep 7. Review.

PMID:
12389114
8.

The role of ras GTPase activating protein in human tumorigenesis.

Friedman E.

Pathobiology. 1995;63(6):348-50. Review.

PMID:
8738474
9.

Signaling through RAS-RAF-MEK-ERK: from basics to bedside.

Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, Troppmair J.

Curr Med Chem. 2007;14(5):601-23. Review.

PMID:
17346150
10.

Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells.

Espino PS, Pritchard S, Heng HH, Davie JR.

Int J Cancer. 2009 Feb 1;124(3):562-7. doi: 10.1002/ijc.23959.

PMID:
19004007
11.

Inhibitors of the ras oncogene as therapeutic targets.

Ghobrial IM, Adjei AA.

Hematol Oncol Clin North Am. 2002 Oct;16(5):1065-88. Review.

PMID:
12512383
12.

The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.

Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y.

Hum Mutat. 2008 Aug;29(8):992-1006. doi: 10.1002/humu.20748. Review.

PMID:
18470943
13.
14.

Therapeutic strategies for targeting ras proteins.

Gysin S, Salt M, Young A, McCormick F.

Genes Cancer. 2011 Mar;2(3):359-72. doi: 10.1177/1947601911412376.

15.

Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway.

Song C, Wang W, Li M, Liu Y, Zheng D.

IUBMB Life. 2009 Jun;61(6):685-92. doi: 10.1002/iub.221.

PMID:
19472191
16.
17.

Deregulated Ras signaling in developmental disorders: new tricks for an old dog.

Schubbert S, Bollag G, Shannon K.

Curr Opin Genet Dev. 2007 Feb;17(1):15-22. Review.

PMID:
17208427
18.

Small GTPase Ras and Rho expression in rat osteoblasts during spaceflight.

Kumei Y, Shimokawa H, Ohya K, Katano H, Akiyama H, Hirano M, Morita S.

Ann N Y Acad Sci. 2007 Jan;1095:292-9.

PMID:
17404041
19.

Ras-driven transformation of human nestin-positive pancreatic epithelial cells.

Campbell PM, Lee KM, Ouellette MM, Kim HJ, Groehler AL, Khazak V, Der CJ.

Methods Enzymol. 2008;439:451-65. doi: 10.1016/S0076-6879(07)00431-4.

PMID:
18374182
20.

Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling.

Kiel C, Serrano L.

Sci Signal. 2009 Jul 28;2(81):ra38. doi: 10.1126/scisignal.2000397.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk